Specifically, in multivariable analysis, sulfonylurea use was associated with an almost 7-fold higher risk of a hypoglycemia-related visit or hospitalization, basal insulin use was associated with a 12.5-fold increase in risk, and basal plus bolus insulin use was associated with an almost 28-fold increase in risk. Here, INS is linked to Hypoglycemia.